Soaraway Tristel cracks US infection control market
The company's participation at APIC 2025, the largest annual infection prevention and control conference in the United States, stirred further interest in its proposition after the official US launch of Tristel OPH, a novel high-level disinfectant for ophthalmic instruments following official clearance from the FDA.
Matt Sassone, CEO of Tristel plc, said: “APIC 2025 marked a significant milestone for our US strategy. The FDA clearance and now successful launch of Tristel OPH opens a valuable new market in ophthalmology and demonstrates our ability to deliver meaningful innovation where it's urgently needed.
“The response to both Tristel OPH and Tristel ULT was overwhelmingly positive, and we are excited about the opportunities ahead.”
APIC 2025 provided a high-impact platform for Tristel to introduce Tristel OPH to the market. The product addresses a significant unmet need in ophthalmology, offering a solution that combines compliance with infection control guidelines and improved clinical workflow efficiency.
Its debut generated exceptional interest from infection prevention professionals, reflecting the urgency for effective, practical alternatives in the reprocessing of ophthalmic medical devices.
A robust pipeline of prospective customers has already been established, with many health systems engaging directly with the Tristel team during the event for live demonstrations and discussions on product evaluation.
Stock availability is expected in August and Tristel is actively supporting US institutions in preparing for clinical trials and internal validation on launch.
The company also showcased Tristel ULT, its FDA-cleared high level disinfectant for ultrasound probes, represented by distribution partner and ultrasound specialist, Parker Laboratories, Inc., and Tristel 3T, the company’s digital traceability platform.
Both products attracted strong interest from new prospects and existing users alike, with particular enthusiasm shown for Tristel ULT’s cost-effectiveness and rapid reprocessing capabilities.
The strong reception at APIC 2025 reinforces Tristel’s accelerating momentum in the US and underlines the increasing demand for innovative and compliant high level disinfection solutions in medical device reprocessing.